MSI Financial Services’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$33K Buy
305
+96
+46% +$10.7K ﹤0.01% 2116
2016
Q3
$25K Sell
209
-201
-49% -$27.1K ﹤0.01% 2235
2016
Q2
$58K Sell
410
-102
-20% -$15K ﹤0.01% 1743
2016
Q1
$67K Buy
512
+259
+102% +$32.2K ﹤0.01% 1562
2015
Q4
$36K Sell
253
-1,390
-85% -$193K ﹤0.01% 1934
2015
Q3
$218K Sell
1,643
-130
-7% -$22.4K 0.02% 625
2015
Q2
$312K Sell
1,773
-38
-2% -$6.83K 0.02% 578
2015
Q1
$313K Sell
1,811
-3
-0.2% -$515 0.02% 582
2014
Q4
$297K Sell
1,814
-567
-24% -$94.1K 0.03% 473
2014
Q3
$382K Buy
2,381
+56
+2% +$8.61K 0.05% 406
2014
Q2
$342K Buy
2,325
+78
+3% +$10.8K 0.05% 419
2014
Q1
$312K Buy
2,247
+780
+53% +$117K 0.04% 398
2013
Q4
$186K Buy
1,467
+573
+64% +$59.3K 0.03% 522
2013
Q3
$82K Sell
894
-40
-4% -$3.23K 0.01% 712
2013
Q2
$64K Buy
+934
New +$57.1K 0.01% 790

Other funds holding JAZZ

MSI Financial Services's JAZZ Position: Q4 2016 in Review

MSI Financial Services increased its Jazz Pharmaceuticals (JAZZ) stake by 46% in Q4 2016, buying an estimated $10.7K and bringing the position to 305 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #2116.

MSI Financial Services first reported a position in JAZZ in Q2 2013 and has held it in 15 quarters since. The position peaked at $382K in Q3 2014. 295 funds tracked by Wall St. Rank hold JAZZ as of Q4 2016.

  • MSI Financial Services held 305 shares of Jazz Pharmaceuticals worth $33K as of Q4 2016.
  • MSI Financial Services bought 96 Jazz Pharmaceuticals shares in Q4 2016, an estimated $10.7K.
  • Jazz Pharmaceuticals made up ﹤0.01% of MSI Financial Services's portfolio in Q4 2016, its #2116 holding.
  • MSI Financial Services first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • MSI Financial Services's Jazz Pharmaceuticals position peaked at $382K in Q3 2014.
  • 295 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2016.

Based on MSI Financial Services's 13F filing for Q4 2016, filed 13 Jan 2017.